Aytu BioPharma Q2 FY2023 revenue $26.3M (+14% YoY); second consecutive positive adjusted EBITDA $0.7M

AYTU BIOPHARMA, INC

2023-Q2 EPS reported -$2.62 revenue$53,934,000

Net revenue $26.3M, up 14% YoY; Rx segment $18.0M (+23%) driven by 95% growth in pediatric products.
Adjusted EBITDA positive $0.7M vs $(7.6)M loss in year-ago quarter; second consecutive positive quarter.
Net loss $(6.7)M ($2.15 per share) improved from $(11.5)M ($8.74 per share) in Q2 FY2022.
Gross margin expanded to 66% from 53% YoY; suspension of clinical programs expected to save over $20M.
Extended interest-only period on Avenue loan to Jan 2024; 1-for-20 reverse stock split regained Nasdaq compliance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AYTU BIOPHARMA, INC reported the quarter ended December 31, 2022 results: revenue $26.3 million.

Period: the quarter ended December 31, 2022
Revenue: $26.3 million
Result: reported results

Exact text from the filing

--- EX-99.1 (EX-99.1) --- Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 Second Consecutive Quarter of Positive Adjusted EBITDA Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment Company to Host Conference Call Today at 5:00 pm ET ENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”)

View on SEC.gov

Browse all earnings releases →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-001642

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.